Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status

This is a prospective, multicenter, randomized controlled trial. The study consists of 3 phases as follows: ‐ Randomization phase: subjects undergo screening, baseline, interim and 90‐day follow‐up visits ‐ PKG+ Group (standard of care clinical evaluation plus use of PKG data) ‐ PKG‐ Group (standard of care clinical evaluation without use of PKG data ‐ the MDS is blinded to PKG data) ‐ Randomization ratio will be 1:1 with assignments generated in advance of the start of the trial by the unblinded statistician who will provide a list containing group assignments that will be available in an Electronic Database (EDC) for site use. ‐ The clinical investigator, study site staff, and subject will not be blinded to the randomization assignment during the randomization phase of the study ‐ Open‐label phase: at the end of the 90‐day randomization phase visit for PKG‐ Group subjects, the MDS will report on the PKG and review it with the subject, the subject will complete follow‐ups with the MDS using the PKG information during the clinical assessment following the same process as the PKG+ Group during the randomization phase ‐ Extended open‐label follow‐up phase: annual follow‐ups for all subjects at 1, 2, and 3 years during which the MDS will use the PKG information during clinical assessments for all subjects.